In veterinary medicine, cancer therapy targeting the PI3K/AKT/mTOR signaling pathway is expected to exhibit antitumor effects against canine mammary cancer [14], hemangiosarcoma [15], and melanoma [16,17]. Here, AKT1 is linked to cancer.